{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T03:56:08Z","timestamp":1776138968947,"version":"3.50.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Gastroenterol Hepatol"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1038\/nrgastro.2009.221","type":"journal-article","created":{"date-parts":[[2010,2,5]],"date-time":"2010-02-05T10:52:14Z","timestamp":1265367134000},"page":"93-101","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Optimizing the safety of biologic therapy for IBD"],"prefix":"10.1038","volume":"7","author":[{"given":"Shanika","family":"de Silva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shane","family":"Devlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Remo","family":"Panaccione","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BFnrgastro2009221_CR1","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/S0016-5085(98)70381-6","volume":"115","author":"C Fiocchi","year":"1998","unstructured":"Fiocchi, C. Inflammatory bowel disease: aetiology and pathogenesis. Gastroenterology 115, 182\u2013205 (1998).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2009221_CR2","unstructured":"REMICADE\u00ae (infliximab) for injection. Prescribing information ( Malvern, P. C., Inc., 2008)."},{"key":"BFnrgastro2009221_CR3","unstructured":"HUMIRA\u00ae (adalimumab). Prescribing information (Abbott Laboratories, 2008)."},{"key":"BFnrgastro2009221_CR4","unstructured":"Cimzia\u00ae (certolizumab pegol). Prescribing information ( Smyrna, G. U., Inc., 2008)."},{"key":"BFnrgastro2009221_CR5","unstructured":"Tysabri\u00ae (natalizumab). Prescribing information (Elan Pharmaceuticals, 2008)."},{"key":"BFnrgastro2009221_CR6","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"SB Hanauer","year":"2002","unstructured":"Hanauer, S. B. et al. Maintenance infliximab for Crohn's disease: the ACCENT 1 randomised trial. Lancet 359, 1541\u20131549 (2002).","journal-title":"Lancet"},{"key":"BFnrgastro2009221_CR7","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","volume":"340","author":"DH Present","year":"1999","unstructured":"Present, D. H. et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N. Engl. J. Med. 340, 1398\u20131405 (1999).","journal-title":"N. Engl. J. Med."},{"key":"BFnrgastro2009221_CR8","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1056\/NEJMoa030815","volume":"350","author":"BE Sands","year":"2004","unstructured":"Sands, B. E. et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N. Engl. J. Med. 350, 876\u2013885 (2004).","journal-title":"N. Engl. J. Med."},{"key":"BFnrgastro2009221_CR9","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/S0016-5085(99)70332-X","volume":"117","author":"P Rutgeerts","year":"1999","unstructured":"Rutgeerts, P. et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 117, 761\u2013769 (1999).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2009221_CR10","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1056\/NEJMoa050516","volume":"353","author":"P Rutgeerts","year":"2005","unstructured":"Rutgeerts, P. et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 353, 2462\u20132476 (2005).","journal-title":"N. Engl. J. Med."},{"key":"BFnrgastro2009221_CR11","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","volume":"132","author":"JF Colombel","year":"2007","unstructured":"Colombel, J. F. et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 132, 52\u201365 (2007).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2009221_CR12","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","volume":"130","author":"SB Hanauer","year":"2006","unstructured":"Hanauer, S. B. et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 130, 323\u2013333 (2006).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2009221_CR13","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1136\/gut.2006.106781","volume":"56","author":"WJ Sandborn","year":"2007","unstructured":"Sandborn, W. J. et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 56, 1232\u20131239 (2007).","journal-title":"Gut"},{"key":"BFnrgastro2009221_CR14","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa067594","volume":"357","author":"WJ Sandborn","year":"2007","unstructured":"Sandborn, W. J. et al. Certolizumab pegol for the treatment of Crohn's disease. N. Engl. J. Med. 357, 228\u2013238 (2007).","journal-title":"N. Engl. J. Med."},{"key":"BFnrgastro2009221_CR15","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1056\/NEJMoa062897","volume":"357","author":"S Schreiber","year":"2007","unstructured":"Schreiber, S. et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N. Engl. J. Med. 357, 239\u2013250 (2007).","journal-title":"N. Engl. J. Med."},{"key":"BFnrgastro2009221_CR16","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1053\/j.gastro.2005.06.064","volume":"129","author":"S Schreiber","year":"2005","unstructured":"Schreiber, S. et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 129, 807\u2013818 (2005).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2009221_CR17","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.cgh.2006.03.002","volume":"4","author":"G Lichtenstein","year":"2006","unstructured":"Lichtenstein, G. et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin. Gastroenterol. Hepatol. 4, 621\u2013630 (2006).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"BFnrgastro2009221_CR18","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1136\/gut.2006.114660","volume":"57","author":"N Viget","year":"2008","unstructured":"Viget, N., Vernier-Massouille, G., Salmon-Ceron, D., Yazdanpanah, Y. & Colombel, J. Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. Gut 57, 549\u2013558 (2008).","journal-title":"Gut"},{"key":"BFnrgastro2009221_CR19","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1053\/j.gastro.2008.01.012","volume":"134","author":"M Toruner","year":"2008","unstructured":"Toruner, M. et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 134, 929\u2013936 (2008).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2009221_CR20","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJMoa011110","volume":"345","author":"J Keane","year":"2001","unstructured":"Keane, J. et al. Tuberculosis associated with inflximab, a tumour necrosis factor alpha-neutralizing agent. N. Engl. J. Med. 345, 1098\u20131104 (2001).","journal-title":"N. Engl. J. Med."},{"key":"BFnrgastro2009221_CR21","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1002\/ibd.20216","volume":"13","author":"C Colbert","year":"2007","unstructured":"Colbert, C., Chavarria, A. & Berkelhammer, C. Fulminant hepatic failure in chronic hepatitis B on withdrawal of corticosteroids, azathioprine and infliximab for Crohn's disease. Inflamm. Bowel Dis. 13, 1453\u20131454 (2007).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFnrgastro2009221_CR22","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1136\/gut.2004.040675","volume":"53","author":"M Esteve","year":"2004","unstructured":"Esteve, M. et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 53, 1363\u20131365 (2004).","journal-title":"Gut"},{"key":"BFnrgastro2009221_CR23","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1016\/j.cgh.2008.05.010","volume":"6","author":"S Caspersen","year":"2008","unstructured":"Caspersen, S. et al. Infliximab for inflammatory bowel disease in Denmark 1999\u20132005: clinical outcome and follow-up evaluation of malignancy and mortality. Clin. Gastroenterol. Hepatol. 6, 1212\u20131217 (2008).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"BFnrgastro2009221_CR24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1053\/j.gastro.2003.10.047","volume":"126","author":"J Colombel","year":"2004","unstructured":"Colombel, J. et al. The safety profile of inflximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 126, 19\u201331 (2004).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2009221_CR25","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","volume":"107","author":"ES Chung","year":"2003","unstructured":"Chung, E. S. et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107, 3133\u20133140 (2003).","journal-title":"Circulation"},{"key":"BFnrgastro2009221_CR26","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1136\/gut.2003.018515","volume":"53","author":"T Ljung","year":"2004","unstructured":"Ljung, T. et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 53, 849\u2013853 (2004).","journal-title":"Gut"},{"key":"BFnrgastro2009221_CR27","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/j.cgh.2009.01.004","volume":"7","author":"CA Siegel","year":"2009","unstructured":"Siegel, C. A., Marden, S., Persing, S. M., Larson, R. J. & Sands, B. E. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin. Gastroenterol. Hepatol. 7, 874\u2013881 (2009).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"BFnrgastro2009221_CR28","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1097\/00054725-200409000-00028","volume":"10","author":"BE Sands","year":"2004","unstructured":"Sands, B. E. et al. Guidelines for immunizations in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 10, 677\u2013692 (2004).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFnrgastro2009221_CR29","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1111\/j.1572-0241.2006.00646.x","volume":"101","author":"GY Melmed","year":"2006","unstructured":"Melmed, G. Y. et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am. J. Gastroenterol. 101, 1834\u20131840 (2006).","journal-title":"Am. J. Gastroenterol."},{"key":"BFnrgastro2009221_CR30","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.cgh.2007.02.035","volume":"5","author":"P Mamula","year":"2007","unstructured":"Mamula, P. et al. Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 5, 851\u2013856 (2007).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"BFnrgastro2009221_CR31","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1002\/ibd.20956","volume":"15","author":"JF Colombel","year":"2009","unstructured":"Colombel, J. F. et al. Adalimumab safety in global clinical trials of patients with Crohn's disease. Inflamm. Bowel Dis. 15, 1308\u20131319 (2009).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFnrgastro2009221_CR32","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1053\/gast.2002.33426","volume":"122","author":"WJ Sandborn","year":"2002","unstructured":"Sandborn, W. J. & Targan, S. R. Biologic therapy of inflammatory bowel disease. Gastroenterology 122, 1592\u20131608 (2002).","journal-title":"Gastroenterology"},{"issue":"Suppl. S1","key":"BFnrgastro2009221_CR33","first-page":"a1116","volume":"108","author":"G Lichtenstein","year":"2008","unstructured":"Lichtenstein, G. et al. Safety of infliximab and other Crohn's disease therapies: Treat Registry Data with 24,575 patient-years of follow up [abstract]. Am. J. Gastroenterol. 108 (Suppl. S1), a1116 (2008).","journal-title":"Am. J. Gastroenterol."},{"issue":"Suppl. DDW","key":"BFnrgastro2009221_CR34","first-page":"a946","volume":"134","author":"G D'Haens","year":"2008","unstructured":"D'Haens, G. et al. Corticosteroids pose an increased risk of serious infection: an interim safety analysis of the ENCORE registry [abstract]. Gastroenterology 134 (Suppl. DDW), a946 (2008).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2009221_CR35","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.crohns.2009.02.010","volume":"3","author":"JF Rahier","year":"2009","unstructured":"Rahier, J. F. et al. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J. Crohn's Colitis 3, 47\u201391 (2009).","journal-title":"J. Crohn's Colitis"},{"key":"BFnrgastro2009221_CR36","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1136\/gut.2008.163642","volume":"58","author":"H Fidder","year":"2009","unstructured":"Fidder, H. et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-center cohort study. Gut 58, 501\u2013508 (2009).","journal-title":"Gut"},{"key":"BFnrgastro2009221_CR37","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1053\/j.gastro.2004.02.070","volume":"126","author":"P Rutgeerts","year":"2004","unstructured":"Rutgeerts, P., Van Assche, G. & Vermeire, S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 126, 1593\u20131610 (2004).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2009221_CR38","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S1542-3565(04)00060-6","volume":"2","author":"WS Mow","year":"2004","unstructured":"Mow, W. S. et al. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin. Gastroenterol. Hepatol. 2, 309\u2013313 (2004).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"BFnrgastro2009221_CR39","doi-asserted-by":"publisher","first-page":"177","DOI":"10.7326\/0003-4819-149-3-200808050-00241","volume":"149","author":"M Pai","year":"2008","unstructured":"Pai, M., Zwerling, A. & Menzies, D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann. Intern. Med. 149, 177\u2013184 (2008).","journal-title":"Ann. Intern. Med."},{"key":"BFnrgastro2009221_CR40","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1002\/ibd.20131","volume":"13","author":"A Lavagna","year":"2007","unstructured":"Lavagna, A. et al. Infliximab and the risk of latent viruses reactivation in active Crohn's disease. Inflamm. Bowel Dis. 13, 896\u2013902 (2007).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFnrgastro2009221_CR41","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.jcv.2008.06.002","volume":"43","author":"V D'Ovidio","year":"2008","unstructured":"D'Ovidio, V. et al. Cytomegalovirus infection in inflammatory bowel disease patients undergoing anti-TNFalpha therapy. J. Clin. Virol. 43, 180\u2013183 (2008).","journal-title":"J. Clin. Virol."},{"key":"BFnrgastro2009221_CR42","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1002\/ibd.20943","volume":"15","author":"GY Melmed","year":"2009","unstructured":"Melmed, G. Y. Vaccination strategies for patients with inflammatory bowel disease on immunomodulators and biologics. Inflamm. Bowel Dis. 15, 1410\u20131416 (2009).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFnrgastro2009221_CR43","unstructured":"[No authors listed] Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 46 (RR-6), 1\u201326 (1998)."},{"key":"BFnrgastro2009221_CR44","unstructured":"[No authors listed] Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 46 (RR-8), 1\u201324 (1997)."},{"key":"BFnrgastro2009221_CR45","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1136\/gut.2006.103564","volume":"56","author":"G D'Haens","year":"2007","unstructured":"D'Haens, G. Risks and benefits of biologic therapy for inflammatory bowel diseases. Gut 56, 725\u2013732 (2007).","journal-title":"Gut"},{"key":"BFnrgastro2009221_CR46","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/S0016-5085(03)00701-7","volume":"125","author":"S Vermeire","year":"2003","unstructured":"Vermeire, S. et al. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology 125, 32\u201339 (2003).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2009221_CR47","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1016\/0016-5085(93)91068-S","volume":"105","author":"P Munkholm","year":"1993","unstructured":"Munkholm, P., Langholz, E., Davidsen, M. & Binder, V. Intestinal cancer risk and mortality in patients with Crohn's disease. Gastroenterology 105, 1716\u20131723 (1993).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2009221_CR48","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.cgh.2008.03.014","volume":"6","author":"L Peyrin-Biroulet","year":"2008","unstructured":"Peyrin-Biroulet, L. et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin. Gastroenterol. Hepatol. 6, 644\u2013653 (2008).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"BFnrgastro2009221_CR49","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/ncpgasthep0695","volume":"4","author":"L Biancone","year":"2007","unstructured":"Biancone, L., Calabrese, E., Petruzziello, C. & Pallone, F. Treatment with biologic therapies and the risk of cancer in patients with IBD. Nat. Clin. Pract. Gastroenterol. Hepatol. 4, 78\u201391 (2007).","journal-title":"Nat. Clin. Pract. Gastroenterol. Hepatol."},{"key":"BFnrgastro2009221_CR50","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1136\/gut.2005.075937","volume":"55","author":"L Biancone","year":"2006","unstructured":"Biancone, L. et al. Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study. Gut 55, 228\u2013233 (2006).","journal-title":"Gut"},{"key":"BFnrgastro2009221_CR51","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1053\/gast.2001.28703","volume":"121","author":"JD Lewis","year":"2001","unstructured":"Lewis, J. D. et al. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology 121, 1080\u20131087 (2001).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2009221_CR52","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1136\/gut.2004.051771","volume":"54","author":"J Askling","year":"2005","unstructured":"Askling, J. et al. Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut 54, 617\u2013622 (2005).","journal-title":"Gut"},{"key":"BFnrgastro2009221_CR53","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1002\/1097-0142(20010215)91:4<854::AID-CNCR1073>3.0.CO;2-Z","volume":"91","author":"CN Bernstein","year":"2001","unstructured":"Bernstein, C. N., Blanchard, J. F., Kleiwer, E. & Wajda, A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 91, 854\u2013862 (2001).","journal-title":"Cancer"},{"key":"BFnrgastro2009221_CR54","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","volume":"295","author":"T Bongartz","year":"2006","unstructured":"Bongartz, T. et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infection and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295, 2275\u20132285 (2006).","journal-title":"JAMA"},{"key":"BFnrgastro2009221_CR55","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/S0140-6736(09)61302-7","volume":"374","author":"L Beaugerie","year":"2009","unstructured":"Beaugerie, L. et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 374, 1617\u20131625 (2009).","journal-title":"Lancet"},{"key":"BFnrgastro2009221_CR56","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1002\/ibd.20169","volume":"13","author":"JR Rosh","year":"2007","unstructured":"Rosh, J. R., Gross, T., Mamula, P., Griffiths, A. & Hyams, J. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale? Inflamm. Bowel Dis. 13, 1024\u20131030 (2007).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFnrgastro2009221_CR57","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1136\/gut.2008.163279","volume":"57","author":"M Shale","year":"2008","unstructured":"Shale, M., Kanfer, E., Panaccione, R. & Ghosh, S. Hepatosplenic T cell lymphoma in inflammatory bowel disease. Gut 57, 1639\u20131641 (2008).","journal-title":"Gut"},{"issue":"Suppl.","key":"BFnrgastro2009221_CR58","first-page":"A2","volume":"130","author":"S Kane","year":"2006","unstructured":"Kane, S., Khatibi, B. & Reddy, D. Use of immunosuppressant results in higher incidence of abnormal PAP smears in women with inflammatory bowel disease. Gastroenterology 130 (Suppl.), A2 (2006).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2009221_CR59","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1053\/j.gastro.2008.10.021","volume":"136","author":"H Singh","year":"2009","unstructured":"Singh, H. et al. Risk of cervical abnormalities in women with inflammatory bowel disease: a population-based nested case\u2013control study. Gastroenterology 136, 451\u2013458 (2009).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2009221_CR60","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1002\/ibd.20959","volume":"15","author":"CW Lees","year":"2009","unstructured":"Lees, C. W. Lack of association between cervical dysplasia and IBD: a large case\u2013control study. Inflamm. Bowel Dis. 15, 1621\u20131629 (2009).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFnrgastro2009221_CR61","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1002\/ibd.20391","volume":"14","author":"S Kane","year":"2008","unstructured":"Kane, S. Abnormal Pap smears in inflammatory bowel disease. Inflamm. Bowel Dis. 14, 1158\u20131160 (2008).","journal-title":"Inflamm. Bowel Dis."},{"issue":"Suppl. II","key":"BFnrgastro2009221_CR62","doi-asserted-by":"crossref","first-page":"ii70","DOI":"10.1136\/ard.62.suppl_2.ii70","volume":"62","author":"S Ghosh","year":"2003","unstructured":"Ghosh, S. alpha 4 integrin blockage in inflammatory bowel disease. Ann. Rheum. Dis. 62 (Suppl. II), ii70\u2013ii72 (2003).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrgastro2009221_CR63","first-page":"38","volume":"7","author":"DE Baker","year":"2007","unstructured":"Baker, D. E. Natalizumab: overview of its pharmacology and safety. Rev. Gastroenterol. Disord. 7, 38\u201346 (2007).","journal-title":"Rev. Gastroenterol. Disord."},{"key":"BFnrgastro2009221_CR64","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1056\/NEJMoa043335","volume":"353","author":"WJ Sandborn","year":"2005","unstructured":"Sandborn, W. J. et al. Natalizumab induction and maintenance therapy for Crohn's disease. N. Engl. J. Med. 353, 1912\u20131925 (2005).","journal-title":"N. Engl. J. Med."},{"key":"BFnrgastro2009221_CR65","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1056\/NEJMoa051782","volume":"353","author":"BK Kleinschmidt-DeMasters","year":"2005","unstructured":"Kleinschmidt-DeMasters, B. K. & Tyler, K. L. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N. Engl. J. Med. 353, 369\u2013374 (2005).","journal-title":"N. Engl. J. Med."},{"key":"BFnrgastro2009221_CR66","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1056\/NEJMoa051847","volume":"353","author":"A Langer-Gould","year":"2005","unstructured":"Langer-Gould, A., Atlas, S. W., Green, A. J., Bollen, A. W. & Pelletier, D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N. Engl. J. Med. 353, 375\u2013381 (2005).","journal-title":"N. Engl. J. Med."},{"key":"BFnrgastro2009221_CR67","unstructured":"Food and Drug Administration. Information on Natalizumab (marketed as Tysabri) Food and Drug Administration [online], (2009)."}],"container-title":["Nature Reviews Gastroenterology &amp; Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/nrgastro.2009.221.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nrgastro.2009.221","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nrgastro.2009.221.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T23:29:05Z","timestamp":1739834945000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrgastro.2009.221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":67,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["BFnrgastro2009221"],"URL":"https:\/\/doi.org\/10.1038\/nrgastro.2009.221","relation":{},"ISSN":["1759-5045","1759-5053"],"issn-type":[{"value":"1759-5045","type":"print"},{"value":"1759-5053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2]]},"assertion":[{"value":"The other authors, the Journal Editor N. Wood and the CME questions author D. Lie declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}